title: Increased serum levels of methylglyoxal-derived hydroimidazolone-AGE are associated with increased cardiovascular disease mortality in nondiabetic women.
abstract: OBJECTIVE
  To investigate the association of the levels of methylglyoxal-derived hydroimidazolone AGE modified proteins (MG-H1-AGE) with cardiovascular disease (CVD) mortality in an 18-year follow-up study in Finnish nondiabetic and diabetic subjects.
  
  
  METHODS
  The study design was a nested case-control study. Serum MG-H1-AGE levels in samples drawn at baseline were measured with a DELFIA type immunoassay in 220 diabetic subjects and 61 nondiabetic subjects who died from CVD during the follow-up, and age- and gender-matched 157 diabetic subjects and 159 nondiabetic subjects who did not die from CVD.
  
  
  RESULTS
  In type 2 diabetic subjects serum MG-H1-AGE levels were similar in subjects who died from CVD and in subjects who did not, 32.6 (24.6-42.1) (median (interquartile range)) vs. 31.3 (22.5-40.7)U/mL (p=0.281). In nondiabetic subjects serum MG-H1 levels were significantly higher in subjects who died from CVD than in subjects who were alive, 35.4 (28.1-44.7) vs. 31.3 (24.2-38.6)U/mL (p=0.025). Corresponding MG-H1 levels were 41.2 (35.6-58.7) vs. 31.1 (26.7-35.7)U/mL, p=0.003, in women, and 34.4 (26.3-41.2) vs. 32.0 (22.8-40.3)U/mL, p=0.270, in men. Multivariate logistic regression analysis showed a significant association of serum levels of MG-H1-AGE with CVD mortality in nondiabetic women (adjusted p=0.021), but not in nondiabetic men.
  
  
  CONCLUSIONS
  Our 18-year follow-up study shows that high baseline serum levels of MG-H1 type of AGE modified proteins were associated with CVD mortality in nondiabetic women, but not in nondiabetic men or in diabetic subjects.
authors.affiliation: Aker and Ullevål Diabetes Research Centre, Oslo, Norway.
authors.forename: Bente K
authors.initials: BK
authors.lastname: Kilhovd
authors.forename: Auni
authors.initials: A
authors.lastname: Juutilainen
authors.forename: Seppo
authors.initials: S
authors.lastname: Lehto
authors.forename: Tapani
authors.initials: T
authors.lastname: Rönnemaa
authors.forename: Peter A
authors.initials: PA
authors.lastname: Torjesen
authors.forename: Kristian F
authors.initials: KF
authors.lastname: Hanssen
authors.forename: Markku
authors.initials: M
authors.lastname: Laakso
mesh_terms: D002318:Cardiovascular Diseases / Q000097:blood* / Q000401:mortality; D016022:Case-Control Studies; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D005260:Female; D005387:Finland; D005500:Follow-Up Studies; D017127:Glycation End Products, Advanced / Q000097:blood*; D006801:Humans; D007093:Imidazoles / Q000097:blood*; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D011765:Pyruvaldehyde / Q000494:pharmacology*; D012044:Regression Analysis; D012737:Sex Factors
chemical_list: D017127:Glycation End Products, Advanced; D007093:Imidazoles; C117197:imidazolone; D011765:Pyruvaldehyde